Differentiation of patients with and without prostate cancer using urine
1H
NMR
metabolite biomarkers
prostate cancer
urine metabolomics
Journal
Magnetic resonance in chemistry : MRC
ISSN: 1097-458X
Titre abrégé: Magn Reson Chem
Pays: England
ID NLM: 9882600
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
09
08
2023
received:
25
04
2023
accepted:
12
08
2023
medline:
27
11
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. For its detection, serum prostate-specific antigen (PSA) screening is commonly used, despite its lack of specificity, high false positive rate, and inability to discriminate indolent from aggressive PCa. Following increases in serum PSA levels, clinicians often conduct prostate biopsies with or without advanced imaging. Nuclear magnetic resonance (NMR)-based metabolomics has proven to be promising for advancing early-detection and elucidation of disease progression, through the discovery and characterization of novel biomarkers. This retrospective study of urine-NMR samples, from prostate biopsy patients with and without PCa, identified several metabolites involved in energy metabolism, amino acid metabolism, and the hippuric acid pathway. Of note, lactate and hippurate-key metabolites involved in cellular proliferation and microbiome effects, respectively-were significantly altered, unveiling widespread metabolomic modifications associated with PCa development. These findings support urine metabolomics profiling as a promising strategy to identify new clinical biomarkers for PCa detection and diagnosis.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
740-747Subventions
Organisme : NIH HHS
ID : AG070257
Pays : United States
Organisme : NIH HHS
ID : CA115746
Pays : United States
Organisme : NIH HHS
ID : CA273010
Pays : United States
Organisme : NIH HHS
ID : OD023406
Pays : United States
Organisme : NIH HHS
ID : AG07025
Pays : United States
Organisme : NIH HHS
ID : AG070257
Pays : United States
Organisme : NIH HHS
ID : CA115746
Pays : United States
Organisme : NIH HHS
ID : CA273010
Pays : United States
Organisme : NIH HHS
ID : OD023406
Pays : United States
Organisme : NIH HHS
ID : AG07025
Pays : United States
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
R. L. Siegel, K. D. Miller, N. S. Wagle, A. Jemal, CA Cancer J. Clin. 2023, 73(1), 17.
R. M. Martin, J. L. Donovan, E. L. Turner, C. Metcalfe, G. J. Young, E. I. Walsh, J. A. Lane, S. Noble, S. E. Oliver, S. Evans, J. A. C. Sterne, P. Holding, Y. Ben-Shlomo, P. Brindle, N. J. Williams, E. M. Hill, S. Y. Ng, J. Toole, M. K. Tazewell, L. J. Hughes, C. F. Davies, J. C. Thorn, E. Down, G. Davey Smith, D. E. Neal, F. C. Hamdy, CAP Trial Group, Jama 2018, 319(9), 883.
P. F. Pinsky, P. C. Prorok, K. Yu, B. S. Kramer, A. Black, J. K. Gohagan, E. D. Crawford, R. L. Grubb, G. L. Andriole, Cancer 2017, 123(4), 592.
F. H. Schröder, J. Hugosson, S. Carlsson, T. Tammela, L. Määttänen, A. Auvinen, M. Kwiatkowski, F. Recker, M. J. Roobol, Eur. Urol. 2012, 62(5), 745.
J. J. Fenton, M. S. Weyrich, S. Durbin, Y. Liu, H. Bang, J. Melnikow, Jama 2018, 319(18), 1914.
C. Pérez-Rambla, L. Puchades-Carrasco, M. García-Flores, J. Rubio-Briones, J. A. López-Guerrero, A. Pineda-Lucena, Metabolomics 2017, 13(5), 52.
B. Yang, C. Zhang, S. Cheng, G. Li, J. Griebel, J. Neuhaus, Diagn. 2021, 11(2), 149.
C. Bruzzone, A. Loizaga-Iriarte, P. Sánchez-Mosquera, R. Gil-Redondo, I. Astobiza, T. Diercks, A. R. Cortazar, A. Ugalde-Olano, H. Schäfer, F. J. Blanco, M. Unda, C. Cannet, M. Spraul, J. M. Mato, N. Embade, A. Carracedo, O. Millet, J. Proteome Res. 2020, 19(6), 2419.
A. R. Lima, J. Pinto, D. Barros-Silva, C. Jerónimo, R. Henrique, M. L. Bastos, M. Carvalho, P. Guedes Pinho, Metabolomics 2020, 16(6), 70.
H. Zheng, B. Dong, J. Ning, X. Shao, L. Zhao, Q. Jiang, H. Ji, A. Cai, W. Xue, H. Gao, Clin. Chim. Acta 2020, 501, 241.
D. Kumar, K. Nath, H. Lal, A. Gupta, Expert Rev. Proteomics 2021, 18(11), 995.
S. Ge, Q. Zhang, Y. Tian, L. Hao, J. Duan, B. Zhang, Clin. Chim. Acta 2020, 510, 291.
E. Sutinen, M. Nurmi, A. Roivainen, M. Varpula, T. Tolvanen, P. Lehikoinen, H. Minn, Eur. J. Nucl. Med. Mol. Imaging 2004, 31(3), 317.
A. R. Lima, J. Pinto, F. Amaro, M. L. Bastos, M. Carvalho, P. Guedes de Pinho, Metabolites 2021, 11(3), 181. https://doi.org/10.3390/metabo11030181
E. Eidelman, J. Twum-Ampofo, J. Ansari, M. Siddiqui, Front. Oncol. 2017, 7, 131.
M. Buszewska-Forajta, F. Monedeiro, A. Gołębiowski, P. Adamczyk, B. Buszewski, Metabolites 2022, 12(3), 268.
C. Deane, Nat. Chem. Biol. 2019, 15(2), 95.
F. J. H. Sorgdrager, P. J. W. Naudé, I. P. Kema, E. A. Nollen, P. P. D. Deyn, Front. Immunol. 2019, 10, 10.
C. Risstalpers, M. C. T. Verleunmooijman, J. Trapman, A. O. Brinkmann, Biochem. Biophys. Res. Commun. 1993, 196(1), 173.
Q. Wang, C. G. Bailey, C. Ng, J. Tiffen, A. Thoeng, V. Minnas, M. L. Lehman, S. C. Hendy, G. Buchanan, C. C. Nelson, J. E. J. Rasko, J. Holst, BMC Proc. 2012, 6(3), P23.
M. E. Brosnan, J. T. Brosnan, J. Nutr. 2020, 150, 2570S.
M. d. l. P. Sarasola, M. A. Táquez Delgado, M. B. Nicoud, V. A. Medina, Pharmacol. Res. Perspect. 2021, 9(5), e00778.
H. Zheng, B. Dong, J. Ning, X. Shao, L. Zhao, Q. Jiang, H. Ji, A. Cai, W. Xue, H. Gao, Clin. Chim. Acta: Int. J. Clin. Chem. 2020, 501, 241.
C. A. Reichard, B. D. Naelitz, Z. Wang, X. Jia, J. Li, M. J. Stampfer, E. A. Klein, S. L. Hazen, N. Sharifi, Cancer Epidemiol. Biomarkers Prevent. 2022, 31(1), 192.